2019 marked the beginning of a new era of cystic fibrosis. The U.S. Food and Drug Administration approved Trikafta® (elexacaftor/tezacaftor/ivacaftor), following decades of perseverance from the CF community; and the CF Foundation announced its $500 million Path to a Cure, a bold scientific agenda to accelerate treatments for the underlying cause of CF for every person with the disease.
Read the 2019 Annual Report to learn about our ongoing work to help people with CF live long, fulfilling lives no matter where they are on their journey, and to make CF stand for Cure Found.